Publications by authors named "P Lallemand"
Article Synopsis
- Biomarker guided therapy can enhance treatment for COVID-19 patients, with a focus on evaluating the effectiveness of point-of-care (POC) antibody tests in this context.* -
- Two POC tests, LumiraDX and RightSign, were assessed for their reliability and ease of use against a standard test, with both showing moderate agreement but differing in accuracy and usability.* -
- The RightSign test was found to be easier to use and more effective at identifying patients without antibodies compared to the LumiraDX test, despite both tests being associated with clinical outcomes.*
Background: Serial measurement of virological and immunological biomarkers in patients admitted to hospital with COVID-19 can give valuable insight into the pathogenic roles of viral replication and immune dysregulation. We aimed to characterise biomarker trajectories and their associations with clinical outcomes.
Methods: In this international, prospective cohort study, patients admitted to hospital with COVID-19 and enrolled in the Therapeutics for Inpatients with COVID-19 platform trial within the Accelerating COVID-19 Therapeutic Interventions and Vaccines programme between Aug 5, 2020 and Sept 30, 2021 were included.
Background: Although antivirals remain important for the treatment COVID-19, methods to assess treatment efficacy are lacking. Here, we investigated the impact of remdesivir on viral dynamics and their contribution to understanding antiviral efficacy in the multicenter Adaptive COVID-19 Treatment Trial 1, which randomized patients to remdesivir or placebo.
Methods: Longitudinal specimens collected during hospitalization from a substudy of 642 patients with COVID-19 were measured for viral RNA (upper respiratory tract and plasma), viral nucleocapsid antigen (serum), and host immunologic markers.
Article Synopsis
- - Researchers analyzed data from a clinical trial involving 400 adults with severe COVID-19 to evaluate biological differences and clinical outcomes related to inflammatory biomarkers and treatment responses.
- - The study found that certain inflammation-related biomarkers were linked to higher mortality rates and identified two distinct subtypes of patients, each demonstrating different patterns of inflammation and injury markers.
- - The overall trial highlighted the complexity of COVID-19 cases and the need to consider biological variability among patients when exploring treatment options, especially immunomodulatory therapies.
Background: Neutralizing monoclonal antibodies (nmAbs) failed to show clear benefit for hospitalized patients with coronavirus disease 2019 (COVID-19). Dynamics of virologic and immunologic biomarkers remain poorly understood.
Methods: Participants enrolled in the Therapeutics for Inpatients with COVID-19 trials were randomized to nmAb versus placebo.